Functional variants in the lipoprotein lipase gene and risk of cardiovascular disease

Current Opinion in Lipidology

Volumn 10, Issue 5, 1999, Pages 393-399

  Hokanson, John E ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Division of Metabolism Endocrinology and Nutrition   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN LIPASE;

ALLELE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DNA POLYMORPHISM; FEMALE; GENETIC SUSCEPTIBILITY; HEART PROTECTION; HUMAN; MALE; PRIORITY JOURNAL; REVIEW;

ALLELES; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEIN LIPASE; RISK FACTORS;

EID: 0033396880     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199910000-00003     Document Type: Review

References (63)

1. 1 Havel RJ, Gordon Jr RS. Idiopathic hyperlipidemia: metabolic studies in an affected family. J Clin Invest 1960; 39:1777-1790.
2. 2 Magill P, Rao SN, Miller NE, Nicoll A, Brunzell J, St Hilaire J, et al. Relationships between the metabolism of high-density and very-low-density lipoproteins in man: studies of apolipoprotein kinetics and adipose tissue lipoprotein lipase activity. Eur J Clin Invest 1982; 12:113-120.
3. 3 Havel RJ, Kane JP. Structure and metabolism of plasma lipoproteins. In: Scriver CR, Beaudet AL, Sly WS, Valle D (editors). The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 1995. pp. 1841-1851.
4. 4 Goldberg IJ, Le NA, Paterniti JR Jr, Ginsberg HN, Lindgren FT, Brown WV. Lipoprotein metabolism during acute inhibition of hepatic triglyceride lipase in the cynomolgus monkey. J Clin Invest 1982; 70:1184-1192.
5. 5 Demant T, Carlson LA, Holmquist L, Karpe F, Nilsson Ehle P, Packard CJ, et al. Lipoprotein metabolism in hepatic lipase deficiency: studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. J Lipid Res 1988; 29:1603-1611.
6. 6 Nikkila EA, Taskinen MR, Kekki M. Relation of plasma high-density lipoprotein cholesterol to lipoprotein-lipase activity in adipose tissue and skeletal muscle of man. Atherosclerosis 1978; 29:497-501.
7. 7 Patsch JR, Gotto AM Jr, Olivercrona T, Eisenberg S. Formation of high density lipoprotein2-like particles during lipolysis of very low density lipoproteins in vitro. Proc Natl Acad Sci USA 1978; 75:4519-4523.
8. 8 Goldberg IJ, Blaner WS, Vanni TM, Moukides M, Ramakrishnan R. Role of lipoprotein lipase in the regulation of high density lipoprotein apolipoprotein metabolism. Studies in normal and lipoprotein lipase-inhibited monkeys. J Clin Invest 1990; 86:463-473.
9. 9 Beisiegel U, Weber W, Bengtsson Olivecrona G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc Natl Acad Sci USA 1991; 88:8342-8346.
10. 10 Mulder M, Lombardi P, Jansen H, van Berkel TJ, Frants RR, Havekes LM. Low density lipoprotein receptor internalizes low density and very low density lipoproteins that are bound to heparan sulfate proteoglycans via lipoprotein lipase. J Biol Chem 1993; 268:9369-9375.
11. 11 Argraves KM, Battey FD, MacCalman CD, McCrae KR, Gafvels M, Kozarsky KF, et al. The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes. J Biol Chem 1995; 270:26550-26557.
12. 12 Salinelli S, Lo J-Y, Mims MP, Zsigmond E, Smith LC, Chan L. Structure-function relationship of lipoprotein lipase-mediated enhancement of very low density lipoprotein binding and catabolism by the low density lipoprotein receptor. J Biol Chem 1996; 271:21906-21913.
13. 13 Edwards IJ, Goldberg IJ, Parks JS, Xu H, Wagner WD. Lipoprotein lipase enhances the interaction of low density lipoproteins with artery-derived extracellular matrix proteoglycans. J Lipid Res 1993; 34:1155-1163.
14. 14 de Beers F, Hendriks WL, van Vark LC, Kamerling SWA, van Dijk KO, Hofker MH, et al. Binding of B-VLDL to heparan sulfate proteoglycans requires lipoprotein lipase, whereas apoE only modulates binding affinity. Arterioscler Thromb Vasc Biol. 1999; 19:633-637. In-vitro binding of beta-VLDL is increased 12-55-fold by the addition of lipoprotein lipase.
15. 15 Auerbach BJ, Cain W, Ansong M, Newton RS, Saxena U, Bisgaier CL. Lipoprotein lipase greatly enhances the retention of lipoprotein (a) to endothelial cell-matrix. Atherosclerosis 1999; 142:89-96.
16. 16 Saxena U, Klein MG, Vanni TM, Goldberg IJ. Lipoprotein lipase increases low density lipoprotein retention by subendothelial cell matrix. J Clin Invest 1992; 89:373-380.
17. 17 Murthy V, Julien P, Gagn'e C. Molecular pathobiology of the human lipoprotein lipase gene. Pharmacol Ther 1996; 70:101-135.
18. 18 Julien P. High frequency of lipoprotein lipase deficiency in the Quebec population. Can J Cardiol 1992; 8:675-676.
19. 19 Mailly F, Tugrul Y, Reymer PW, Bruin T, Seed M, Groenemeyer BF, et al. A common variant in the gene for lipoprotein lipase (Asp9 to Asn). Functional implications and prevalence in normal and hyperlipidemic subjects. Arterioscler Thromb Vasc Biol 1995; 15:468-478.
20. 20 Mailly F, Fisher RM, Nicaud V, Luong L-A, Evans AE, Marques-Vidal P, et al. Association between the LPL-D9N mutation in the lipoprotein lipase gene and plasma lipid traits in myocardial infarction survivors form the ECTIM study. Atherosclerosis 1996; 122:21-28.
21. 21 Assmann G, Cullen P, Schulte H. Risk factors - from epidemiology to genetics in the Munster Heart Study (PROCAM). 66th Congress of the European Atherosclerosis Society. Florence: Foundazione Giovanni Lorenzini; 1996. p. 29.
22. 22 Hata A, Robertson M, Emi M, Lalouel JM. Direct detection and automated sequencing of individual alleles after electrophoretic strand separation: identification of a common nonsense mutation in exon 9 of the human lipoprotein lipase gene. Nucleic Acids Res 1990; 18:5407-5411.
23. 23 Peacock RE, Hamsten A, Nilsson Ehle P, Humphries SE. Associations between lipoprotein lipase gene polymorphisms and plasma correlations of lipids, lipoproteins and lipase activities in young myocardial infarction survivors and age-matched healthy individuals from Sweden. Atherosclerosis 1992; 97:171-185.
24. 24 Mattu RK, Needham EW, Morgan R, Rees A, Hackshaw AK, Stocks J, et al. DNA variants at the LPL gene locus associate with angiographically defined severity of atherosclerosis and serum lipoprotein levels in a Welsh population. Arterioscler Thromb 1994; 14:1090-1097.
25. 25 Hokanson JE. Lipoprotein lipase gene variants and risk of coronary disease: a quantitative analysis of population-based studies. Int J Clin Lab Res 1997; 27:24-34.
26. 26 Zhang Q, Cavanna J, Winkelman BR, Shine B, Gross W, Marz W, et al. Common genetic variants of lipoprotein lipase that relate to lipid transport in patients with premature coronary artery disease. Clinical Genetics 1995; 48:293-298.
27. 27 Yang W-S, Nevin DN, Iwasaki L, Peng R, Brown BG, Brunzell JD, et al. Regulatory mutations in the human lipoprotein lipase gene in patients with familial combined hyperlipidemia and coronary artery disease. J Lipid Res 1996; 37:2627-2637.
28. 28 Kastelein JJ, Groenemeyer BE, Hallman DM, Henderson H, Reymer PW, Gagn'e SE, et al. The Asn9 variant of lipoprotein lipase is associated with the - 93G promoter mutation and an increased risk of coronary artery disease. The Regress Study Group. Clin Genet 1998; 53:27-33. The authors report strong linkage disequilibrium between the lipoprotein lipase D9N and - 93T to G mutations in Dutch men, and a significant increase in the frequency of this allele among documented coronary disease individuals from the REGRESS study population.
29. 29 Elbein SC, Yeager C, Kwong LK, Lingam A, Inoue I, Lalouel JM, et al. Molecular screening of the lipoprotein lipase gene in hypertriglyceridemic members of familial noninsulin-dependent diabetes mellitus families. J Clin Endocrinol Metab 1994; 79:1450-1456.
30. 30 De Bruin TWA, Mailly F, Van Barlingen HHJJ, Fisher R, Castro Cabezas M, Talmud P, et al. Lipoprotein lipase gene mutations D9N and N291S in four pedigrees with familial combined hyperlipidemia. J Clin Invest 1996; 26:631-639.
31. 31 Hall S, Chu G, Miller G, Cruickshank K, Cooper JA, Humphries SE, et al. A common mutation in the lipoprotein lipase gene promoter, - 93T/G, is associated with lower plasma triglyceride levels and increased promoter activity in vitro. Arterioscler Thromb Vasc Biol 1997; 17:1969-1976.
32. 32 Ehrenborg E, Clee SM, Pimstone SN, Reymer PW, Benlian P, Hoogendijk CF, et al. Ethnic variation and in vivo effects of the - 93t to g promoter variant in the lipoprotein lipase gene. Arterioscler Thromb Vasc Biol 1997; 17:2672-2678.
33. 33 Hoffer MJ, Bredie SJ, Snieder H, Reymer PW, Demacker PN, Havekes LM, et al. Gender-related association between the - 93T to G/D9N haplotype of the lipoprotein lipase gene and elevated lipid levels in familial combined hyperlipidemia. Atherosclerosis 1998; 138:91-99. Among families with familial combined hyperlipidemia, the lipoprotein lipase D9N/ - 93T to G haplotype contributed to dyslipidemia in men only.
34. 34 Jukema JW, van Boven AJ, Groenemeijer B, Zwinderman AH, Reiber JHC, Bruschke AVG, et al. The asp9asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. Circulation 1996; 94:1913-1918.
35. 35 Talmud PJ, Hall S, Holleran S, Ramakrishnan R, Ginsberg HN, Humphries SE. LPL promoter 93T/G transition influences fasting and postprandial plasma triglycerides response in African-Americans and Hispanics. J Lipid Res 1998; 39:1189-1196. The lipoprotein lipase 93T to G substitution is associated with a decrease in triglyceride and an increase in postprandial triglyceride clearance in the presence of the lipoprotein lipase position 9 D allele.
36. 36 Rouis M, Lohse P, Dugi KA, Lohse P, Beg OU, Ronan R, et al. Homozygosity for two point mutations in the lipoprotein lipase (LPL) gene in a patient with familial LPL deficiency: LPL(Asp9 to Asn, Tyr262 to His). J Lipid Res 1996; 37:651-661.
37. 37 Zhang H, Henderson H, Gagne SE, Clee SM, Miao L, Liu G, et al. Common sequence variants of lipoprotein lipase: standardized studies of in vitro expression and catalytic function. Biochim Biophys Acta 1996; 1302:159-166.
38. 38 Zambon A, Hokanson JE, Brown BG, Brunzell JB. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 1999; 99:1959-1964. The authors report that LDL density changes due to hepatic lipase account for the largest proportion of coronary disease regression on intensive lipid lowering therapy.
39. 39 Nordestgaard BG, Abildgaard S, Wittrup HH, Steffensen R, Jensen G, Tybjaerg Hansen A. Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation 1997; 96:1737-1744.
40. 40 Minnich A, Baloukas J, Roederer G, Lussier Cacan S, Davignon J, Genest J Jr. Lipoprotein lipase gene mutations in coronary artery disease. Can J Cardiol 1998; 14:711-716.
41. 41 Emi M, Wilson DE, Iverius PH, Wu L, Hata A, Hegele R, et al. Missense mutation (Gly to - Glu188) of human lipoprotein lipase imparting functional deficiency. J Biol Chem 1990; 265:5910-5916.
42. 42 Wilson DE, Emi M, Iverius PH, Hata A, Wu LL, Hillas E, et al. Phenotypic expression of heterozygous lipoprotein lipase deficiency in the extended pedigree of a proband homozygous for a missense mutation. J Clin Invest 1990; 86:735-750.
43. 43 Miesenbock G, Holzl B, Foger B, Brandstatter E, Paulweber B, Sandhofer F, et al. Heterozygous lipoprotein lipase deficiency due to a missense mutation as the cause of impaired triglyceride tolerance with multiple lipoprotein abnormalities. J Clin Invest 1993; 91:448-455.
44. 44 Hokanson J, Brunzell J, Jarvik G, Wijsman E, Austin M. Linkage of low-density lipoprotein size to the lipoprotein lipase gene in heterozygous lipoprotein lipase deficiency. Am J Hum Genet 1999; 64:608-618. The authors find significant evidence for genetic linkage of small LDL to functional mutations in the lipoprotein lipase gene in heterozygous lipoprotein lipase deficiency.
45. 45 Reymer PW, Gagn'e E, Groenemeyer BE, Zhang H, Forsyth I, Jansen H, et al. A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nat Genet 1995; 10:28-34.
46. 46 Fisher RM, Mailly F, Peacock RE, Hamsten A, Seed M, Yudkin JS, et al. Interaction of the lipoprotein lipase asparagine 291 to serine mutation with body mass index determines elevated plasma triacylglycerol concentrations: a study in hyperlipidemic subjects, myocardial infarction survivors, and healthy adults. J Lipid Res 1995; 36:2104-2112.
47. 47 Wittrup HH, Tybjaerg-Hansen A, Abildgaard S, Steffensen R, Schnohr P, Nordestgaard BG. A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. J Clin Invest 1997; 99:1606-1613.
48. 48 Huang P, Kostulas K, Huang WX, Crisby M, Kostulas V, Hillert J. Lipoprotein lipase gene polymorphisms in ischaemic stroke and carotid stenosis. Eur J Clin Invest 1997; 27:740-742.
49. 49 Wittekoek ME, Pimstone SN, Reymer PW, Feuth L, Botma GJ, Defesche JC, et al. A common mutation in the lipoprotein lipase gene (N291S) alters the lipoprotein phenotype and risk for cardiovascular disease in patients with familial hypercholesterolemia. Circulation 1998; 97:729-735. This study shows that the lipoprotein lipase N291S allele is associated with a three-fold increase in cardiovascular disease among men with familial hypercholesterolemia.
50. 50 Jemaa R, Fumeron F, Poirier O, Lecerf L, Evans A, Arveiler D, et al. Lipoprotein lipase gene polymorphisms: associations with myocardial infarction and lipoprotein levels, the ECTIM study. Etude Cas Témoin sur l'Infarctus du Myocarde. J Lipid Res 1995; 36:2141-2146.
51. 51 Pimstone SN, Clee SM, Gagn'e SE, Miao L, Zhang H, Stein EA, et al. A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) results in altered postprandial chylomicron triglyceride and retinyl palmiate response in normolipidemic carriers. J Lipid Res 1996; 37:1675-1684.
52. 52 Hoffer MJV, Bredie SJH, Boomsma DI, Reymer PWA, Kastelein JJP, de Knijff P, et al. The lipoprotein lipase (Asn291 to Ser) mutation is associated with elevated lipid levels in families with familial combined hyperlipidemia. Atherosclerosis 1996; 119:159-167.
53. 53 Zhang H, Reymer PW, Liu MS, Forsythe IJ, Groenemeyer BE, Frohlich J, et al. Patients with apoE3 deficiency (E2/2, E3/2, and E4/2) who manifest with hyperlipidemia have increased frequency of an Asn 291 to Ser mutation in the human LPL gene. Arterioscler Thromb Vasc Biol 1995; 15:1695-1703.
54. 54 Busca R, Peinado J, Vilella E, Auwerx J, Deeb SS, Vilar'o S, et al. The mutant Asn291 to Ser human lipoprotein lipase is associated with reduced catalytic activity and does not influence binding to heparin. FEBS Lett 1995; 367:257-262.
55. 55 Zhang Q, Cavallero E, Cavanna J, Kay A, Charles A, Braschi S, et al. Lipemia, diabetes m, obesity: mutations at the lipoprotein lipase (LPL) gene locus. 66th Congress of the European Atherosclerosis Society. Florence: Foundazione Giovanni Lorenzini; 1996. p. 34.
56. 56 Gerdes C, Fisher RM, Nicaud V, Boer J, Humphries SE, Talmud PJ, et al. Lipoprotein lipase variants D9N and N291S are associated with increased plasma triglyceride and lower high-density lipoprotein cholesterol concentrations: studies in the fasting and postprandial states: the European Atherosclerosis Research Studies. Circulation 1997; 96:733-740.
57. 57 Reymer PW, Groenemeyer BE, Gagn'e E, Miao L, Appelman EE, Seidel JC, et al. A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia. Hum Mol Genet 1995; 4:1543-1549.
58. 58 Sass C, Zannad F, Herbeth B, Salah D, Chapet O, Siest G, et al. Apolipoprotein E4, lipoprotein lipase C447 and angiotensin-I converting enzyme deletion alleles were not associated with increased wall thickness of carotid and femoral arteries in healthy subjects from the Stanislas cohort. Atherosclerosis 1998; 140:89-95.
59. 59 Groenemeijer BE, Hallman MD, Reymer PW, Gagn'e E, Kuivenhoven JA, Bruin T, et al. Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser447-stop substitution in the lipoprotein lipase gene. REGRESS Study Group. Circulation 1997; 95:2628-2635.
60. 60 Humphries SE, Nicaud V, Margalef J, Tiret L, Talmud PJ. Lipoprotein lipase gene variation is associated with a paternal history of premature coronary artery disease and fasting and postprandial plasma triglycerides: the European Atherosclerosis Research Study (EARS). Arterioscler Thromb Vasc Biol 1998; 18:526-534. This study reports a significant decrease of the lipoprotein lipase S447X allele in individuals with a family history of premature coronary disease.
61. 61 Kobayashi J, Nishida T, Ameis D, Stahnke G, Schotz MC, Hashimoto H et al. A heterozygous mutation (the codon for Ser447-a stop codon) in lipoprotein lipase contributes to a defect in lipid interface recognition in a case with type I hyperlipidemia. Biochem Biophys Res Commun 1992; 182:70-77.
62. 62 Nykjaer A, Nielsen M, Lookene A, Meyer N, Roigaard H, Etzerodt M, et al. A carboxyl-terminal fragment of lipoprotein lipase binds to the low density lipoprotein receptor-related protein and inhibits lipase-mediated uptake of lipoprotein in cells. J Biol Chem 1994; 269:31747-31755.
63. 63 Gofman JW, DeLalla O, Flazier F, Freeman NK, Lindgren FT, Nichols AV, et al. The serum lipoprotein transport system in health, metabolic disorders, atherosclerosis, and coronary disease. Plasma 1954; 2:413-483.